219 related articles for article (PubMed ID: 34673001)
41. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
42. Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
Waqas M; Halim SA; Alsalman A; Khan A; Elkord E; Al-Harrasi A
J Biomol Struct Dyn; 2023; 41(24):14771-14785. PubMed ID: 36927289
[TBL] [Abstract][Full Text] [Related]
43. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
44. Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation.
DiFrancesco M; Hofer J; Aradhya A; Rufinus J; Stoddart J; Finocchiaro S; Mani J; Tevis S; Visconti M; Walawender G; DiFlumeri J; Fattakhova E; Patil SP
Comput Biol Chem; 2023 Feb; 102():107804. PubMed ID: 36610303
[TBL] [Abstract][Full Text] [Related]
45. Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction.
Kim EH; Ning B; Kawamoto M; Miyatake H; Kobatake E; Ito Y; Akimoto J
J Mater Chem B; 2020 Nov; 8(44):10162-10171. PubMed ID: 33095222
[TBL] [Abstract][Full Text] [Related]
46. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
47. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Dai X; Wang K; Chen H; Huang X; Feng Z
Bioorg Chem; 2021 Sep; 114():105034. PubMed ID: 34116264
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
[TBL] [Abstract][Full Text] [Related]
50. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
51. Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics.
Wu X; Wang N; Liang J; Wang B; Jin Y; Liu B; Yang Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674929
[TBL] [Abstract][Full Text] [Related]
52. Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors.
Russomanno P; Assoni G; Amato J; D'Amore VM; Scaglia R; Brancaccio D; Pedrini M; Polcaro G; La Pietra V; Orlando P; Falzoni M; Cerofolini L; Giuntini S; Fragai M; Pagano B; Donati G; Novellino E; Quintavalle C; Condorelli G; Sabbatino F; Seneci P; Arosio D; Pepe S; Marinelli L
J Med Chem; 2021 Nov; 64(21):16020-16045. PubMed ID: 34670084
[TBL] [Abstract][Full Text] [Related]
53. Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
Veluswamy P; Wacker M; Scherner M; Wippermann J
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142805
[TBL] [Abstract][Full Text] [Related]
54. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
[TBL] [Abstract][Full Text] [Related]
55. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?
Musielak B; Kocik J; Skalniak L; Magiera-Mularz K; Sala D; Czub M; Stec M; Siedlar M; Holak TA; Plewka J
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374878
[No Abstract] [Full Text] [Related]
56. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.
Klyukin K; Alexandrov V
Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362
[TBL] [Abstract][Full Text] [Related]
57. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
59. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
60. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.
Magiera-Mularz K; Skalniak L; Zak KM; Musielak B; Rudzinska-Szostak E; Berlicki Ł; Kocik J; Grudnik P; Sala D; Zarganes-Tzitzikas T; Shaabani S; Dömling A; Dubin G; Holak TA
Angew Chem Int Ed Engl; 2017 Oct; 56(44):13732-13735. PubMed ID: 28881104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
